Your browser doesn't support javascript.
loading
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program.
Kwakkenbos, Linda; Østbø, Nora; Carrier, Marie-Eve; Nielson, Warren R; Fedoruk, Claire; Levis, Brooke; Henry, Richard S; Pope, Janet; Frech, Tracy; Gholizadeh, Shadi; Johnson, Sindhu R; Piotrowski, Pamela; Jewett, Lisa R; Gordon, Jessica; Chung, Lorinda; Bilsker, Dan; Tao, Lydia; Turner, Kimberly A; Cumin, Julie; Welling, Joep; Fortuné, Catherine; Leite, Catarina; Gottesman, Karen; Sauvé, Maureen; Reyna, Tatiana Sofia Rodriguez; Hudson, Marie; Larche, Maggie; van Breda, Ward; Suarez-Almazor, Maria E; Bartlett, Susan J; Malcarne, Vanessa L; Mayes, Maureen D; Boutron, Isabelle; Mouthon, Luc; Benedetti, Andrea; Thombs, Brett D.
Affiliation
  • Kwakkenbos L; Department of Clinical Psychology, Radboud University, Montessorilaan 3, 6525, HR, Nijmegen, The Netherlands. kwakkenbosl@gmail.com.
  • Østbø N; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Carrier ME; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Nielson WR; St. Joseph's Health Care, London, Ontario, Canada.
  • Fedoruk C; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Levis B; Centre for Prognosis Research, School of Medicine, Keele University, Staffordshire, UK.
  • Henry RS; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Pope J; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Frech T; Department of Medicine, University of Western Ontario, London, Ontario, Canada.
  • Gholizadeh S; Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
  • Johnson SR; California School of Professional Psychology/Alliant, Los Angeles, CA, USA.
  • Piotrowski P; Toronto Scleroderma Program, Mount Sinai Hospital & Toronto Western Hospital, Toronto, Ontario, Canada.
  • Jewett LR; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Gordon J; Private practice - Nutrition, Hamilton, Ontario, Canada.
  • Chung L; Department of Psychology, Institute of Community and Family Psychiatry, Jewish General Hospital, Montreal, Quebec, Canada.
  • Bilsker D; Department of Medicine, Hospital for Special Surgery, New York City, NY, USA.
  • Tao L; Department of Medicine, Stanford University, Palo Alto, CA, USA.
  • Turner KA; Department of Medicine Palo Alto VA Health Care System, Palo Alto, CA, USA.
  • Cumin J; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Welling J; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  • Fortuné C; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Leite C; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Gottesman K; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Sauvé M; NVLE Dutch patient organization for Systemic Autoimmune Diseases, Utrecht, The Netherlands.
  • Reyna TSR; Ottawa Scleroderma Support Group, Ottawa, Ontario, Canada.
  • Hudson M; University of Minho, Braga, Portugal.
  • Larche M; Scleroderma Foundation, Los Angeles, CA, USA.
  • van Breda W; Scleroderma Canada, Hamilton, Ontario, Canada.
  • Suarez-Almazor ME; Scleroderma Society of Ontario, Hamilton, Ontario, Canada.
  • Bartlett SJ; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico.
  • Malcarne VL; Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
  • Mayes MD; Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Boutron I; Department of Medicine, McMaster University and St Joseph's Healthcare, Hamilton, Ontario, Canada.
  • Mouthon L; Faculty of Behavioural and Movement Sciences, Vrije University, Amsterdam, The Netherlands.
  • Benedetti A; Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Thombs BD; Department of Medicine, McGill University, Montreal, Quebec, Canada.
Pilot Feasibility Stud ; 8(1): 45, 2022 Feb 26.
Article in En | MEDLINE | ID: mdl-35219340
ABSTRACT

BACKGROUND:

The Scleroderma Patient-centered Intervention Network (SPIN) developed an online self-management program (SPIN-SELF) designed to improve disease-management self-efficacy in people with systemic sclerosis (SSc, or scleroderma). The aim of this study was to evaluate feasibility aspects for conducting a full-scale randomized controlled trial (RCT) of the SPIN-SELF Program.

METHODS:

This feasibility trial was embedded in the SPIN Cohort and utilized the cohort multiple RCT design. In this design, at the time of cohort enrollment, cohort participants consent to be assessed for trial eligibility and randomized prior to being informed about the trial. Participants in the intervention arm are informed and provide consent, but not the control group. Forty English-speaking SPIN Cohort participants from Canada, the USA, or the UK with low disease-management self-efficacy (Self-Efficacy for Managing Chronic Disease Scale [SEMCD] score ≤ 7) who were interested in using an online self-management program were randomized (32 ratio) to be offered the SPIN-SELF Program or usual care for 3 months. Program usage was examined via automated usage logs. User satisfaction was assessed with semi-structured interviews. Trial personnel time requirements and implementation challenges were logged.

RESULTS:

Of 40 SPIN Cohort participants randomized, 26 were allocated to SPIN-SELF and 14 to usual care. Automated eligibility and randomization procedures via the SPIN Cohort platform functioned properly, except that two participants with SEMCD scores > 7 (scores of 7.2 and 7.3, respectively) were included, which was caused by a system programming error that rounded SEMCD scores. Of 26 SPIN Cohort participants offered the SPIN-SELF Program, only 9 (35%) consented to use the program. Usage logs showed that use of the SPIN-SELF Program was low 2 of 9 users (22%) logged into the program only once (median = 3), and 4 of 9 (44%) accessed none or only 1 of the 9 program's modules (median = 2).

CONCLUSIONS:

The results of this study will lead to substantial changes for the planned full-scale RCT of the SPIN-SELF Program that we will incorporate into a planned additional feasibility trial with progression to a full-scale trial. These changes include transitioning to a conventional RCT design with pre-randomization consent and supplementing the online self-help with peer-facilitated videoconference-based groups to enhance engagement. TRIAL REGISTRATION clinicaltrials.gov , NCT03914781 . Registered 16 April 2019.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Qualitative_research Aspects: Implementation_research Language: En Journal: Pilot Feasibility Stud Year: 2022 Document type: Article Affiliation country: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Qualitative_research Aspects: Implementation_research Language: En Journal: Pilot Feasibility Stud Year: 2022 Document type: Article Affiliation country: Países Bajos